



**Karolinska
Institutet**

Karolinska Institutet

<http://openarchive.ki.se>

This is a Peer Reviewed Accepted version of the following article, accepted for publication in *Best Practice & Research: Clinical Gastroenterology*.

2018-01-08

Tobacco smoking, alcohol consumption and gastro-oesophageal reflux disease

Ness-Jensen, Eivind; Lagergren, Jesper

Best Pract Res Clin Gastroenterol. 2017 Oct;31(5):501-508.

<http://doi.org/10.1016/j.bpg.2017.09.004>

<http://hdl.handle.net/10616/46176>

If not otherwise stated by the Publisher's Terms and conditions, the manuscript is deposited under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.



**Karolinska
Institutet**

This is an author produced version of a paper accepted by **Best Practice & Research: Clinical Gastroenterology**. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Tobacco smoking, alcohol consumption and gastro-oesophageal reflux disease

Ness-Jensen, Eivind; Lagergren, Jesper

Best Pract Res Clin Gastroenterol. 2017 Oct;31(5):501-508

DOI: [10.1016/j.bpg.2017.09.004](https://doi.org/10.1016/j.bpg.2017.09.004)

Access to the published version may require subscription.
Published with permission from: **Elsevier**

Title

Tobacco smoking, alcohol consumption and gastro-oesophageal reflux disease

Authors

Eivind Ness-Jensen (corresponding author), MD PhD

Upper Gastrointestinal Surgery, Department of Molecular medicine and Surgery, Karolinska
Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden

HUNT Research Centre, Department of General Practice and Nursing, NTNU, Norwegian University of
Science and Technology, Forskningsvegen 2, 7600 Levanger, Norway

Medical Department, Levanger Hospital, Nord-Trøndelag Hospital Trust, P.O. Box 333, 7601
Levanger, Norway

Email: eivind.ness-jensen@ki.se

Phone: +47 918 60 549

Jesper Lagergren, MD PhD

Upper Gastrointestinal Surgery, Department of Molecular medicine and Surgery, Karolinska
Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden

School of Cancer Sciences, King's College London, SE1 9RT, United Kingdom

Email: jesper.lagergren@ki.se

Phone: +46 (0) 8-517 760 12

Word count

6964

Abstract

Gastro-oesophageal reflux disease (GORD) develops when reflux of gastric content causes troublesome symptoms or complications. The main symptoms are heartburn and acid regurgitation and complications include oesophagitis, strictures, Barrett's oesophagus and oesophageal adenocarcinoma. In addition to hereditary influence, GORD is associated with lifestyle factors, mainly obesity. Tobacco smoking is regarded as an aetiological factor of GORD, while alcohol consumption is considered a triggering factor of reflux episodes and not a causal factor. Yet, both tobacco smoking and alcohol consumption can reduce the lower oesophageal sphincter pressure, facilitating reflux. In addition, tobacco smoking reduces the production of saliva rich in bicarbonate, which is important for buffering and clearance of acid in the oesophagus. Alcohol also has a direct noxious effect on the oesophageal mucosa, which predisposes to acidic injury. Tobacco smoking cessation reduces the risk of GORD symptoms and avoidance of alcohol is encouraged in individuals where alcohol consumption triggers reflux.

Keywords

Gastroesophageal Reflux; Ethanol; Tobacco; Smoking; Causality; Disease Management

A. Introduction

Gastro-oesophageal reflux disease (GORD) is defined as a condition which develops when reflux of gastric content causes troublesome symptoms or complications [1]. The main symptoms are heartburn (a burning sensation behind the breastbone) and acid regurgitation (a sour taste in the mouth or throat) [2]. These symptoms are experienced occasionally by most people in the general population without being regarded as troublesome, and throughout the population there is a continuum of frequency and severity of reflux symptoms. Mild symptoms occurring two or more days a week or moderate to severe symptoms occurring more than one day a week are often considered troublesome and usually affect the health related quality of life [3, 4]. In epidemiological research, GORD is defined as at least weekly heartburn or regurgitation [5].

GORD is highly prevalent in most parts of the world. In Europe, America and Australia the prevalence is between 9% and 28%, while in East Asia the prevalence is lower, between 3% and 8% [6]. The prevalence is higher in more recent studies and seems to be increasing over time in the same population [7]. The incidence of GORD is about 5 per 1000 person-years [6].

Complications of GORD include mucosal erosions (oesophagitis), peptic strictures, intestinal metaplasia (Barrett's oesophagus) and oesophageal adenocarcinoma. In addition, several extra-oesophageal manifestations might be associated with GORD, e.g. chronic cough, laryngitis, asthma, pneumonia and dental erosions. These manifestations are believed to be due to laryngopharyngeal reflux and micro aspirations to the lungs or due to reflexes mediated by the vagal nerves [8]. However, the extra-oesophageal manifestations are usually multifactorial and GORD is rarely the sole cause [1].

In clinical practice, the diagnosis of GORD is typically based on cardinal symptoms of heartburn or regurgitation and symptom relief after a short course of acid-inhibiting medical treatment, usually a proton pump inhibitor (PPI) [9]. If the symptoms do not resolve, the patient may be referred to an upper gastrointestinal endoscopy where oesophagitis, peptic strictures and

Barrett's oesophagus are diagnostic [10]. However, these complications are not sensitive markers of GORD. In a Swedish endoscopy survey, oesophagitis was present only in 29% of participants with weekly heartburn or regurgitation [11]. If the endoscopy is not diagnostic, a 24 hour oesophageal pH measurement might reveal pathological acidic reflux (fraction time with oesophageal pH <4) [12]. The pH measurement can also be combined with an impedance measurement to detect weakly acidic or non-acidic reflux, the latter typically refractory to acid-inhibiting medical treatment [13].

A. Anatomy and physiology

The anatomy and physiology of the gastro-oesophageal junction is of great importance in GORD. The lower oesophageal sphincter (LOS), the narrow angle where the oesophagus enters the stomach (the angle of His) and the tight opening (hiatus) of the crural diaphragm where the oesophagus enters the abdomen together create an anti-reflux barrier [14]. When reflux appears the refluxed material is cleared from the oesophagus by gravity and peristaltic movements [15] and residual acid is neutralised by swallowed saliva rich in bicarbonate [16]. In addition, tight junctions in the oesophageal epithelia and the lipid-rich matrix in the intercellular spaces protect the mucosa from acidic damage and bicarbonate in the extracellular space buffers acid that reaches deeper than the mucosal surface [17, 18].

A. Pathophysiology

A sliding hiatal hernia is an anatomical disruption of the anti-reflux barrier where a portion of the proximal stomach is located in the thoracic cavity. Such herniation counteracts the flap valve mechanism created by the angle of His [19]. In addition, the hernia impairs clearance of acid from the oesophagus by trapping acid in the hernia [20, 21]. A large hernia also impairs the pinchcock-like action of the diaphragm on the oesophagus [22].

The most common mechanism of reflux is transient lower oesophageal sphincter relaxations (TLOSRS) [15, 23]. TLOSRS are relaxations of the LOS and the crural diaphragm not triggered by swallowing [24], which is a physiological mechanism that allows belching [25, 26]. In GORD patients, there is an increased pressure gradient over the gastro-oesophageal junction and increased compliance of the junction which facilitates reflux when TLOSRS appear [27, 28]. In some GORD patients the LOS resting pressure is hypotensive [29], which allows reflux to occur more easily when the LOS pressure is overcome by an abrupt increase in the intra-abdominal pressure, i.e. strain-induced reflux [23, 30].

B. Tobacco smoking

Tobacco smoking can induce gastro-oesophageal reflux by reducing the LOS resting pressure, as shown by several studies from the 1970s [31-33]. In a study of six male healthy volunteers without GORD, inhalation of cigarette smoking decreased the LOS pressure 37% within two to three minutes, while puffing an unlit cigarette did not induce any change in the LOS pressure [31]. The pressure remained low until smoking was stopped and then the pressure returned towards normal. In a study evaluating 25 daily smokers with heartburn, cigarette smoking caused a fall in the LOS pressure with 41% within one to four minutes [32]. The pressure returned to baseline within three to eight minutes after having stopped smoking and puffing an unlit cigarette did not change the LOS pressure. In this study, pH measurements also showed increased reflux during and after tobacco smoking. In a study of 10 asymptomatic individuals and 10 symptomatic GORD patients, the LOS pressure was not significantly different at baseline, but was reduced by 19% and 21%, respectively, during cigarette smoking [33]. In a study of nine smokers without GORD and nine smokers with GORD, the majority of reflux episodes occurred during coughing and deep inspiration, associated with abrupt increased intra-abdominal pressure which overcame the LOS pressure [34]. The probable mechanism of tobacco induced LOS pressure reduction is blocking of cholinergic receptors by nicotine and subsequent relaxation of the circular LOS muscle fibres [35, 36].

Tobacco smoking is also associated with prolonged acid clearance time, probably due to reduced salivary secretion rate and bicarbonate concentration [37, 38]. In a study of eight non-smokers and 16 daily cigarette smokers without GORD, smoking resulted in an immediate prolongation of the acid clearance time and reduced salivary secretion rate [37]. Moreover, the acid clearance time was prolonged and the salivary secretion rate was lower among smokers who refrained from smoking during the study compared to non-smokers, suggesting a long-lasting negative effect of tobacco smoking. There was also a parallel, but less pronounced, reduction in the bicarbonate concentration among smokers. The reduced acid clearance time is most likely the result of reduced salivary secretion rate. In another study examining 11 daily smokers without GORD symptoms, salivary bicarbonate secretion increased following tobacco smoking cessation, suggesting a benefit in GORD patients [38].

B. Alcohol consumption

Similar to tobacco smoking, alcohol consumption might also reduce the LOS resting pressure. In a study of 20 healthy volunteers without GORD, white wine (8% alcohol) reduced the LOS resting pressure, but not red wine (12% alcohol), even with a higher alcoholic percentage in the red wine consumed [39]. There was no difference in the LOS resting pressure between red wine and tap-water. Consumption of white wine was also followed by increased fraction time with oesophageal pH <4. Red wine also induced GORD symptoms and reflux episodes, but not a pathological fraction time of pH <4 in the oesophagus. In a study of 24 healthy volunteers, beer (7% alcohol) also increased the median fraction time of pH <4 compared to water, but the values were still within the normal range [40]. In this study, an ethanol solution of 7.5% was also compared to tap-water, without showing any difference in the fraction time of pH <4. These findings suggest that other ingredients in wine and beer rather than alcohol promotes reflux among consumers of these alcoholic-containing beverages.

In a study of 12 healthy volunteers without GORD, pH measurements showed significantly increased reflux after ingestion of 180 ml vodka compared with 180 ml water [41]. In a study of 17

healthy volunteers without GORD, ingestion of 120 ml whiskey (40% alcohol) induced supine nightly reflux events assessed by pH measurements that were not apparent during the control night after a placebo drink [42]. A study of acute alcohol intoxication (300 ml whiskey with 43% alcohol during one hour) in twelve volunteers without GORD showed reduced incidence of primary peristalsis in the distal oesophagus, but the oesophageal motor function was normal eight hours after the intoxication [43]. One of the volunteers experienced transient heartburn after the ingestion. Deterioration of oesophageal peristalsis can be found in patients with alcoholic neuropathy [44]. However, this deterioration could have multiple causes related to alcoholism.

Alcohol might also have direct effects on the oesophageal mucosa. In a study of rabbits, an oesophageal mucosal exposure to 10% ethanol had a direct noxious effect on the epithelium, which predisposed to acidic injury [45].

A. Aetiology

Large population-based cohort studies provide the best evidence of the aetiological factors of GORD. The population-based cohort design is less prone to selection bias compared to e.g. hospital-based studies or case-control studies. Large studies also provide more precise estimates of associations with sufficient statistical power to detect weaker associations and to conduct robust sub-analyses. In recent population-based studies, GORD is typically defined as at least weekly symptoms of heartburn or regurgitation.

The aetiology of GORD includes both genetic and lifestyle-related factors. The risk of GORD is increased within families [46] and there is a higher concordance in the prevalence of GORD in monozygotic over dizygotic twin pairs, suggesting a 23% to 39% genetic influence [47, 48]. Obesity is the strongest lifestyle-related risk factor of GORD, especially visceral obesity [49-52]. High dietary

fibre intake and moderate physical exercise, on the other hand, seem to protect against the development of GORD [53].

B. Tobacco smoking

In most studies, tobacco smoking has been associated with an increased risk of developing GORD (Table) [46, 47, 52-60]. The association between tobacco smoking and GORD is seemingly of weak or moderate strength with most reported odds ratios (ORs) below 2. In the largest study on the topic, a nested case-cohort study from Norway with 43,363 participants, the adjusted ORs for GORD were 1.7 (95% CI 1.5 to 1.9) among daily smokers with more than 20 years of smoking history and 1.6 (95% CI 1.3 to 2.0) among smokers with a lifetime number of more than 200,000 cigarettes [53]. A small case-control study from Albania with 845 participants reported very high risk estimates for GORD, with adjusted OR of 9.8 (95% CI 4.2 to 22.7) among former smokers and 29.3 (95% CI 13.9 to 61.2) among current smokers [60]. Both increased duration and amount of tobacco smoking are dose-dependently associated with an increased risk of GORD [53, 54, 56].

In a Norwegian cohort study with 14,916 participants, the adjusted OR of new-onset GORD was 1.4 (95% CI 1.1 to 1.8) among previous smokers and 1.3 (95% CI 1.0 to 1.7) among current smokers [52]. In this study, also individuals who quit smoking during the study period had remaining increased risk of new-onset GORD, with adjusted of OR 1.7 (95% CI 1.3 to 2.3), but this association was explained by gain in weight upon quitting smoking. In a smaller longitudinal case-control study from the United Kingdom with 3418 participants, the risk of new-onset GORD following tobacco smoking did not reach statistical significance at the 1% level, with adjusted OR of 1.3 (99% CI 0.9 to 2.0) [61]. Several smaller studies have failed to find any association between tobacco smoking and GORD [61-64], but this could be due to limited statistical power.

B. Alcohol consumption

Most studies have failed to identify any aetiological association between alcohol consumption and GORD (Table) [47, 52, 53, 62-64]. Some data, however, indicate that high alcohol intake is moderately associated with GORD. In a case-control study from the United States, intake of more than seven drinks per week was associated with increased risk of GORD, with an adjusted OR of 1.9 (95% CI 1.1 to 1.3) [46]. A Japanese case-control study found that heavy drinkers (more than 38 mL/day) had an increased risk of GORD, with an adjusted OR of 1.6 (95% CI 1.1 to 2.3) [54]. A case-control study from the United Kingdom reported an association between excessive alcohol consumption (more than 30 units per week for men and more than 20 units per week for women) and GORD, with an adjusted OR of 3.0 (95% CI 1.5 to 6.1) [55]. An Albanian case-control study found that moderate to heavy alcohol intake was associated with GORD, with an adjusted OR of 1.8 (95% CI 1.1 to 3.1) [60].

However, the largest studies have not identified any association between alcohol consumption and GORD [52, 53]. In the largest study available, a nested case-cohort study from Norway with 43,363 participants, more than ten occasions with alcohol consumption during the last two weeks were not associated with any increased risk of developing GORD, adjusted OR 1.0 (95% CI 0.8 to 1.3), and there was no dose-response association with increasing consumption (p for trend 0.54) [53]. In a Swedish case-control study of 27,717 twins, increasing alcohol intake even indicated a dose-dependent decreased risk of GORD in the monozygotic co-twin control comparison among women (p for trend 0.0093), with adjusted OR of 0.31 (95% CI 0.11 to 0.84) with an alcohol intake of more than 2400 grams per month [56]. However, when the consumption of beer, wine and spirits was analysed separately, no association with GORD was evident. This, together with lack of such association among men in the same study, suggests that chance might be an explanation of the inverse association.

A prospective Norwegian cohort study with 14,916 participants found that at least weekly consumption of alcohol did not influence the risk of new-onset GORD, with an adjusted OR of 0.9

(95% CI 0.7 to 1.2) [52], and a longitudinal case-control study from the United Kingdom with 3418 participants found no increased risk of new-onset GORD, with adjusted OR of 0.6 (95% CI 0.3 to 1.0) [65].

A. Management

The management of patients with GORD can be based on lifestyle modification, medical treatment, and anti-reflux surgery.

B. Lifestyle modification

The best evidence of lifestyle modification in GORD is for weight loss, tobacco smoking cessation, head of bed elevation **during sleep**, very low-carbohydrate diet, diet rich in dietary fibres and avoiding meals before bedtime [9, 66-70]. In addition, it is recommended to avoid dietary factors whenever these are perceived as triggering factors of reflux episodes by the individual patient, i.e. coffee, alcohol, chocolate, peppermint, citrus, carbonated drinks and spicy foods.

C. Tobacco smoking cessation

In a prospective population-based cohort study from Norway including 29,610 participants, smoking cessation was associated with decreased heartburn and acid regurgitations in normal weight individuals using acid-inhibiting medical treatment, compared to participants who continued smoking daily, with an adjusted OR of 5.7 (95% CI 1.4 to 23.6) [71]. However, smoking cessation was not associated with improvement in GORD in overweight (BMI between 25.0 and 29.9) or obese (BMI above 30.0) individuals, with adjusted ORs of 1.2 (95% CI 0.6 to 2.7) and 1.3 (95% CI 0.5 to 3.2), respectively. This could be explained by the strong association between obesity and GORD, compared to the weaker association between tobacco smoking and GORD. In obese individuals, the pathophysiological mechanism driving reflux might be dictated by weight, with tobacco smoking

playing a minor or no role, while in normal weight individuals with GORD, tobacco smoking might be a more important pathophysiological factor [71].

In addition, two small studies have assessed the immediate effects of cigarette smoking cessation on pH measurements in GORD patients [72, 73]. In eight male daily smokers with GORD, abstaining from cigarette smoking for one day decreased the number of reflux episodes in the upright position, but not the total oesophageal acid exposure [72]. In another study, examining 14 daily smokers with GORD, cigarette smoking increased the fraction time of pH<4 and reduced the frequency of heartburn after abstaining for smoking for 48 hours [73].

C. Alcohol abstinence

Based on the available pathophysiological and aetiological evidence, alcohol is mainly considered an instant trigger of reflux, rather than a causal risk factor of GORD, and no long-term interventional studies of alcohol abstinence in GORD exist.

In the current clinical management guidelines avoidance of alcohol use as a treatment of GORD has little or no place [9, 68-70]. However, whenever the individual patient experiences alcohol consumption as a trigger of GORD symptoms, alcohol abstinence or moderation is recommended.

B. Medical and surgical treatment

Medical treatment of GORD mainly consists of acid-inhibiting treatment aimed at reducing the acidity of the refluxed content. With mild and infrequent reflux symptoms without any signs of complications, antacids, sucralphate or alginate are recommended. These medications are rapidly acting, but the duration of the effect is short [69]. With more severe and frequent symptoms of GORD or in individuals with oesophagitis or Barrett's oesophagus, proton pump inhibitors (PPIs) are recommended and long-term use is often needed to prevent recurrence [74] and possibly prevent adenocarcinoma [75]. In the long-term time frame (26 to 52 weeks), PPI therapy reduces the risk of

relapsing oesophagitis and controls symptoms better than H₂-receptor antagonists, which in turn are better than placebo [74, 76, 77].

Medical treatment may last for an indefinite period of time with high costs for patients and society [78, 79]. In addition, long-term and potent acid inhibition with PPIs may be associated with specific adverse effects, including secondary hypergastrinaemia with rebound hypersecretion of acid upon withdrawal of PPIs [80, 81]. Moreover, hypoacidity is associated with increased risk of infections and malabsorption [82-87].

Anti-reflux surgery with fundoplication is presently mainly used for selected patients. Fundoplication repairs the reflux barrier and controls both acid and non-acid reflux, including bile salts and pancreatic juice [88], which could be beneficial for patients intolerant of PPIs or with persistent troublesome regurgitation despite PPI therapy [69]. Fundoplication is as effective as treatment with PPIs in preventing recurrence of oesophagitis and resolving of heartburn, and better in the controlling of acid regurgitation [89, 90]. On the other hand, patients who have undergone surgery have higher rates of dysphagia, bloating and flatulence [89, 90].

A. Practice Points

- Tobacco smoking cessation should be advised to all smokers with GORD.
- Avoidance or moderation of alcohol consumption should be advised to individual patients with GORD if the patient perceives alcohol consumption as a triggering factor of reflux episodes.

A. Research Agenda

- The documentation of treatment effect of tobacco smoking cessation or alcohol abstinence in GORD is sparse.
- Randomized clinical trials assessing the role of tobacco smoking cessation and alcohol consumption in the aetiology of GORD will never be performed due to the ethical problems with continued use of tobacco and alcohol in a trial.
- Large prospective population-based observational studies should be performed to assess whether tobacco smoking cessation and alcohol abstinence are associated with reduced symptoms and complications of GORD. Ideally, such studies should include endoscopic assessments and pH and impedance measurements.
- **Non-randomized intervention studies should also be performed targeting alcohol and smoking behaviours as part of lifestyle modifications in patients with GORD.**

A. Summary

Tobacco smoking and alcohol consumption reduces the LOS resting pressure. In addition, tobacco smoking reduces salivary bicarbonate secretion and increases acid clearance time in the oesophagus.

Alcohol has direct noxious effects on the oesophageal mucosa, predisposing for acidic injury.

Tobacco smoking is a causal aetiological factor of GORD, while alcohol consumption is a triggering factor of reflux episodes among individuals with GORD, but not a risk factor for developing GORD.

Tobacco smoking cessation may reduce GORD symptoms. However, tobacco smoking is only a weak risk factor of GORD and other lifestyle modifications, including weight loss, and medical treatment are usually of greater importance in the treatment of GORD. Whether tobacco smoking cessation prevents or improves the complications of GORD is not known. No long-term interventional studies of alcohol abstinence in GORD exist. Ideally, randomized clinical trials of tobacco smoking cessation and alcohol abstinence should be performed to answer the question of the effect on GORD, including symptoms and complications, but such trials are not feasible due to the ethical problems. Large and

prospective population-based cohort studies and non-randomized intervention studies targeting alcohol and smoking behaviours are more realistic alternatives.

A. Conflict of Interest Statement

None.

A. Acknowledgement

The authors are funded by the Swedish Research Council. The funder had no role in the collection, analysis or interpretation of data or in the writing of the manuscript.

A. References

1. *Vakil, N., et al., *The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus*. American Journal of Gastroenterology, 2006. **101**(8): p. 1900-20; quiz 1943.
2. Klauser, A.G., N.E. Schindlbeck, and S.A. Muller-Lissner, *Symptoms in gastro-oesophageal reflux disease*. Lancet, 1990. **335**(8683): p. 205-8.
3. Wiklund, I., J. Carlsson, and N. Vakil, *Gastroesophageal reflux symptoms and well-being in a random sample of the general population of a Swedish community*. American Journal of Gastroenterology, 2006. **101**(1): p. 18-28.
4. Ronkainen, J., et al., *Gastro-oesophageal reflux symptoms and health-related quality of life in the adult general population--the Kalixanda study*. Alimentary Pharmacology and Therapeutics, 2006. **23**(12): p. 1725-33.
5. *Dent, J., et al., *Epidemiology of gastro-oesophageal reflux disease: a systematic review*. Gut, 2005. **54**(5): p. 710-7.
6. El-Serag, H.B., et al., *Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review*. Gut, 2014. **63**(6): p. 871-80.
7. Ness-Jensen, E., et al., *Changes in prevalence, incidence and spontaneous loss of gastro-oesophageal reflux symptoms: a prospective population-based cohort study, the HUNT study*. Gut, 2012. **61**(10): p. 1390-7.

8. Smith, J., A. Woodcock, and L. Houghton, *New developments in reflux-associated cough*. Lung, 2010. **188 Suppl 1**: p. S81-6.
9. Armstrong, D., et al., *Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004*. Can J Gastroenterol, 2005. **19**(1): p. 15-35.
10. Tefera, L., et al., *Can the combination of symptoms and endoscopy confirm the presence of gastroesophageal reflux disease?* Am Surg, 1997. **63**(10): p. 933-6.
11. Ronkainen, J., et al., *High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report*. Scandinavian Journal of Gastroenterology, 2005. **40**(3): p. 275-85.
12. Kahrilas, P.J. and E.M. Quigley, *Clinical esophageal pH recording: a technical review for practice guideline development*. Gastroenterology, 1996. **110**(6): p. 1982-96.
13. Hirano, I. and J.E. Richter, *ACG practice guidelines: esophageal reflux testing*. American Journal of Gastroenterology, 2007. **102**(3): p. 668-85.
14. Mittal, R.K. and D.H. Balaban, *The esophagogastric junction*. New England Journal of Medicine, 1997. **336**(13): p. 924-32.
15. Dent, J., et al., *Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects*. Journal of Clinical Investigation, 1980. **65**(2): p. 256-67.
16. Helm, J.F., et al., *Effect of esophageal emptying and saliva on clearance of acid from the esophagus*. New England Journal of Medicine, 1984. **310**(5): p. 284-8.
17. Orlando, R.C., et al., *Barriers to paracellular permeability in rabbit esophageal epithelium*. Gastroenterology, 1992. **102**(3): p. 910-23.
18. Orlando, R.C., J.C. Bryson, and D.W. Powell, *Mechanisms of H⁺ injury in rabbit esophageal epithelium*. American Journal of Physiology, 1984. **246**(6 Pt 1): p. G718-24.
19. Delattre, J.F., et al., *The crura of the diaphragm and diaphragmatic passage. Applications to gastroesophageal reflux, its investigation and treatment*. Anatomia Clinica, 1985. **7**(4): p. 271-83.
20. Mittal, R.K., R.C. Lange, and R.W. McCallum, *Identification and mechanism of delayed esophageal acid clearance in subjects with hiatus hernia*. Gastroenterology, 1987. **92**(1): p. 130-5.
21. Sloan, S. and P.J. Kahrilas, *Impairment of esophageal emptying with hiatal hernia*. Gastroenterology, 1991. **100**(3): p. 596-605.
22. Sloan, S., A.W. Rademaker, and P.J. Kahrilas, *Determinants of gastroesophageal junction incompetence: hiatal hernia, lower esophageal sphincter, or both?* Annals of Internal Medicine, 1992. **117**(12): p. 977-82.
23. Dodds, W.J., et al., *Mechanisms of gastroesophageal reflux in patients with reflux esophagitis*. New England Journal of Medicine, 1982. **307**(25): p. 1547-52.
24. Holloway, R.H., R. Penagini, and A.C. Ireland, *Criteria for objective definition of transient lower esophageal sphincter relaxation*. American Journal of Physiology, 1995. **268**(1 Pt 1): p. G128-33.

25. McNally, E.F., J.E. Kelly, Jr., and F.J. Ingelfinger, *Mechanism of Belching: Effects of Gastric Distension with Air*. Gastroenterology, 1964. **46**: p. 254-9.
26. Wyman, J.B., et al., *Control of belching by the lower oesophageal sphincter*. Gut, 1990. **31**(6): p. 639-46.
27. Frankhuisen, R., et al., *Increased intragastric pressure gradients are involved in the occurrence of acid reflux in gastroesophageal reflux disease*. Scandinavian Journal of Gastroenterology, 2009. **44**(5): p. 545-50.
28. Pandolfino, J.E., et al., *Esophagogastric junction opening during relaxation distinguishes nonhernia reflux patients, hernia patients, and normal subjects*. Gastroenterology, 2003. **125**(4): p. 1018-24.
29. Kahrilas, P.J., et al., *Esophageal peristaltic dysfunction in peptic esophagitis*. Gastroenterology, 1986. **91**(4): p. 897-904.
30. Dent, J., et al., *Factors that influence induction of gastroesophageal reflux in normal human subjects*. Digestive Diseases and Sciences, 1988. **33**(3): p. 270-5.
31. Dennish, G.W. and D.O. Castell, *Inhibitory effect of smoking on the lower esophageal sphincter*. New England Journal of Medicine, 1971. **284**(20): p. 1136-7.
32. Stanciu, C. and J.R. Bennett, *Smoking and gastro-oesophageal reflux*. British Medical Journal, 1972. **3**(5830): p. 793-5.
33. Chattopadhyay, D.K., M.G. Greaney, and T.T. Irvin, *Effect of cigarette smoking on the lower oesophageal sphincter*. Gut, 1977. **18**(10): p. 833-5.
34. Kahrilas, P.J. and R.R. Gupta, *Mechanisms of acid reflux associated with cigarette smoking*. Gut, 1990. **31**(1): p. 4-10.
35. Ellis, F.G., R. Kauntze, and J.R. Trounce, *The innervation of the cardia and lower oesophagus in man*. Br J Surg, 1960. **47**: p. 466-72.
36. Misiewicz, J.J., et al., *Achalasia of the cardia: pharmacology and histopathology of isolated cardiac sphincteric muscle from patients with and without achalasia*. Q J Med, 1969. **38**(149): p. 17-30.
37. Kahrilas, P.J. and R.R. Gupta, *The effect of cigarette smoking on salivation and esophageal acid clearance*. Journal of Laboratory and Clinical Medicine, 1989. **114**(4): p. 431-8.
38. Trudgill, N.J., et al., *Impact of smoking cessation on salivary function in healthy volunteers*. Scandinavian Journal of Gastroenterology, 1998. **33**(6): p. 568-71.
39. Pehl, C., et al., *Different effects of white and red wine on lower esophageal sphincter pressure and gastroesophageal reflux*. Scandinavian Journal of Gastroenterology, 1998. **33**(2): p. 118-22.
40. Pehl, C., et al., *Low-proof alcoholic beverages and gastroesophageal reflux*. Digestive Diseases and Sciences, 1993. **38**(1): p. 93-6.
41. Kaufman, S.E. and M.D. Kaye, *Induction of gastro-oesophageal reflux by alcohol*. Gut, 1978. **19**(4): p. 336-8.

42. Vitale, G.C., et al., *The effect of alcohol on nocturnal gastroesophageal reflux*. JAMA, 1987. **258**(15): p. 2077-9.
43. Hogan, W.J., S.R. Viegas de Andrade, and D.H. Winship, *Ethanol-induced acute esophageal motor dysfunction*. J Appl Physiol, 1972. **32**(6): p. 755-60.
44. Winship, D.H., et al., *Deterioration of esophageal peristalsis in patients with alcoholic neuropathy*. Gastroenterology, 1968. **55**(2): p. 173-8.
45. Bor, S., et al., *Esophageal exposure to ethanol increases risk of acid damage in rabbit esophagus*. Dig Dis Sci, 1999. **44**(2): p. 290-300.
46. Locke, G.R., 3rd, et al., *Risk factors associated with symptoms of gastroesophageal reflux*. American Journal of Medicine, 1999. **106**(6): p. 642-9.
47. Mohammed, I., et al., *Genetic influences in gastro-oesophageal reflux disease: a twin study*. Gut, 2003. **52**(8): p. 1085-9.
48. Cameron, A.J., et al., *Gastroesophageal reflux disease in monozygotic and dizygotic twins*. Gastroenterology, 2002. **122**(1): p. 55-9.
49. Hampel, H., N.S. Abraham, and H.B. El-Serag, *Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications*. Annals of Internal Medicine, 2005. **143**(3): p. 199-211.
50. Corley, D.A. and A. Kubo, *Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis*. American Journal of Gastroenterology, 2006. **101**(11): p. 2619-28.
51. Nilsson, M., et al., *Obesity and estrogen as risk factors for gastroesophageal reflux symptoms*. JAMA, 2003. **290**(1): p. 66-72.
52. *Hallan, A., et al., *Risk Factors on the Development of New-Onset Gastroesophageal Reflux Symptoms. A Population-Based Prospective Cohort Study: The HUNT Study*. Am J Gastroenterol, 2015. **110**(3): p. 393-400.
53. *Nilsson, M., et al., *Lifestyle related risk factors in the aetiology of gastro-oesophageal reflux*. Gut, 2004. **53**(12): p. 1730-5.
54. Watanabe, Y., et al., *Cigarette smoking and alcohol consumption associated with gastro-oesophageal reflux disease in Japanese men*. Scandinavian Journal of Gastroenterology, 2003. **38**(8): p. 807-11.
55. Mohammed, I., P. Nightingale, and N.J. Trudgill, *Risk factors for gastro-oesophageal reflux disease symptoms: a community study*. Alimentary Pharmacology and Therapeutics, 2005. **21**(7): p. 821-7.
56. *Zheng, Z., et al., *Lifestyle factors and risk for symptomatic gastroesophageal reflux in monozygotic twins*. Gastroenterology, 2007. **132**(1): p. 87-95.
57. Nasser-Moghaddam, S., et al., *Epidemiological study of gastro-oesophageal reflux disease: reflux in spouse as a risk factor*. Alimentary Pharmacology and Therapeutics, 2008. **28**(1): p. 144-53.
58. Eslick, G.D. and N.J. Talley, *Gastroesophageal reflux disease (GERD): risk factors, and impact on quality of life-a population-based study*. Journal of Clinical Gastroenterology, 2009. **43**(2): p. 111-7.

59. Friedenber, F.K., et al., *Prevalence and risk factors for gastroesophageal reflux disease in an impoverished minority population*. *Obes Res Clin Pract*, 2010. **4**(4): p. e261-e269.
60. Cela, L., et al., *Lifestyle characteristics and gastroesophageal reflux disease: a population-based study in Albania*. *Gastroenterol Res Pract*, 2013. **2013**: p. 936792.
61. Ford, A.C., et al., *The natural history of gastro-oesophageal reflux symptoms in the community and its effects on survival: a longitudinal 10-year follow-up study*. *Aliment Pharmacol Ther*, 2013. **37**(3): p. 323-31.
62. Nandurkar, S., et al., *Relationship between body mass index, diet, exercise and gastro-oesophageal reflux symptoms in a community*. *Alimentary Pharmacology and Therapeutics*, 2004. **20**(5): p. 497-505.
63. Zagari, R.M., et al., *Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study*. *Gut*, 2008. **57**(10): p. 1354-9.
64. Pandeya, N., A.C. Green, and D.C. Whiteman, *Prevalence and determinants of frequent gastroesophageal reflux symptoms in the Australian community*. *Diseases of the Esophagus*, 2011.
65. Ruigomez, A., et al., *Natural history of gastro-oesophageal reflux disease diagnosed in general practice*. *Alimentary Pharmacology and Therapeutics*, 2004. **20**(7): p. 751-60.
66. *Ness-Jensen, E., et al., *Lifestyle Intervention in Gastroesophageal Reflux Disease*. *Clin Gastroenterol Hepatol*, 2015.
67. *Kaltenbach, T., S. Crockett, and L.B. Gerson, *Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach*. *Archives of Internal Medicine*, 2006. **166**(9): p. 965-71.
68. Kahrilas, P.J., et al., *American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease*. *Gastroenterology*, 2008. **135**(4): p. 1383-1391, 1391 e1-5.
69. Kahrilas, P.J., N.J. Shaheen, and M.F. Vaezi, *American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease*. *Gastroenterology*, 2008. **135**(4): p. 1392-1413, 1413 e1-5.
70. Katz, P.O., L.B. Gerson, and M.F. Vela, *Guidelines for the diagnosis and management of gastroesophageal reflux disease*. *Am J Gastroenterol*, 2013. **108**(3): p. 308-28; quiz 329.
71. *Ness-Jensen, E., et al., *Tobacco smoking cessation and improved gastroesophageal reflux: a prospective population-based cohort study: the HUNT study*. *Am J Gastroenterol*, 2014. **109**(2): p. 171-7.
72. Waring, J.P., et al., *The immediate effects of cessation of cigarette smoking on gastroesophageal reflux*. *American Journal of Gastroenterology*, 1989. **84**(9): p. 1076-8.
73. Kadakia, S.C., et al., *Effect of cigarette smoking on gastroesophageal reflux measured by 24-h ambulatory esophageal pH monitoring*. *American Journal of Gastroenterology*, 1995. **90**(10): p. 1785-90.

74. Donnellan, C., et al., *Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease*. Cochrane Database Syst Rev, 2005(2): p. CD003245.
75. Singh, S., et al., *Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis*. Gut, 2014. **63**(8): p. 1229-37.
76. Khan, M., et al., *Medical treatments in the short term management of reflux oesophagitis*. Cochrane Database Syst Rev, 2007(2): p. CD003244.
77. Sigterman, K.E., et al., *Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease*. Cochrane Database Syst Rev, 2013. **5**: p. CD002095.
78. Ofman, J.J., *The economic and quality-of-life impact of symptomatic gastroesophageal reflux disease*. American Journal of Gastroenterology, 2003. **98**(3 Suppl): p. S8-S14.
79. Mason, J. and A.P. Hungin, *Review article: gastro-oesophageal reflux disease--the health economic implications*. Alimentary Pharmacology and Therapeutics, 2005. **22 Suppl 1**: p. 20-31.
80. Waldum, H.L., et al., *Marked increase in gastric acid secretory capacity after omeprazole treatment*. Gut, 1996. **39**(5): p. 649-53.
81. Reimer, C., et al., *Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy*. Gastroenterology, 2009. **137**(1): p. 80-7, 87 e1.
82. Bavishi, C. and H.L. Dupont, *Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection*. Aliment Pharmacol Ther, 2011. **34**(11-12): p. 1269-81.
83. Johnstone, J., K. Nerenberg, and M. Loeb, *Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia*. Aliment Pharmacol Ther, 2010. **31**(11): p. 1165-77.
84. Ngamruengphong, S., et al., *Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies*. Am J Gastroenterol, 2011. **106**(7): p. 1209-18; quiz 1219.
85. Laine, L., et al., *Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors*. Alimentary Pharmacology and Therapeutics, 2000. **14**(6): p. 651-68.
86. Hess, M.W., et al., *Systematic review: hypomagnesaemia induced by proton pump inhibition*. Alimentary Pharmacology and Therapeutics, 2012. **36**(5): p. 405-13.
87. Deshpande, A., et al., *Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis*. Clin Gastroenterol Hepatol, 2012. **10**(3): p. 225-33.
88. del Genio, G., et al., *Total fundoplication controls acid and nonacid reflux: evaluation by pre- and postoperative 24-h pH-multichannel intraluminal impedance*. Surgical Endoscopy, 2008. **22**(11): p. 2518-23.
89. Lundell, L., et al., *Seven-year follow-up of a randomized clinical trial comparing proton-pump inhibition with surgical therapy for reflux oesophagitis*. British Journal of Surgery, 2007. **94**(2): p. 198-203.

90. Galmiche, J.P., et al., *Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial*. JAMA, 2011. **305**(19): p. 1969-77.

Table. Risk of gastro-oesophageal reflux disease (GORD) with tobacco smoking and alcohol consumption

First author	Pub. year	Country	Study design	Number of participants	Response rate	Number of cases	Data	Case definition	Prevalent or incident cases	Risk of GORD with tobacco smoking	Risk of GORD with alcohol consumption	Adjustments*
Locke ⁴⁶	1999	USA	Population-based cross sectional case-control	1524	72%	872	Questionnaire	At least weekly heartburn or acid regurgitation during the prior year	Prevalent	Never cigarette use, OR 1.0 (reference); current cigarette use, OR 1.3 (95% CI 0.8-2.1); past cigarette use, OR 1.6 (95% CI 1.1-2.3).	Alcohol drinks per week: None, OR 1.0 (reference); 1-2, OR 1.0 (95% CI 0.6-1.6); 3-6, OR 1.3 (95% CI 0.8-2.1); 7+, OR 1.9 (95% CI 1.1-3.3).	Age, gender, psychosomatic symptom checklist score, BMI, smoking cigarette use , alcohol use , coffee use , ASA/NSAIDs, relative and spouse history.
Mohammed ⁴⁷	2003	UK	Population-based cross sectional case-control twin	5032	56%	906	Questionnaire	At least weekly heartburn or acid regurgitation during the past year	Prevalent	Ever smoked, OR 1.31 (95% CI 1.10–1.54).	Excess alcohol intake (>28 units/week for men, >21 units/week for women), OR 0.99 (95% CI 0.99–1.00).	Age, smoking, alcohol, BMI, drug therapy, sex, handedness, parental family history of upper gastrointestinal disease.
Watanabe ⁵⁴	2003	Japan	Population-based cross sectional case-control	4188	86%	276	Questionnaire	At least twice weekly heartburn or acid regurgitation the past one year	Prevalent	Lifelong non-smokers, OR 1.00 (reference); former smokers, OR 1.32 (95% CI 0.89–1.96); current smokers, OR 1.35 (95% CI 1.01–1.82). Pack-years of cigarette smoking: 0, OR 1.0 (reference); 0.1-20.0, OR 1.29 (95% CI 0.87-1.90); >20.1, OR 1.45 (95% CI 1.04–2.04); p for trend 0.034.	Daily alcohol drinking (mL/day): non-drinkers, OR 1.25 (95% CI 0.85–1.85); light drinkers (0–15), OR 1.00 (reference); moderate drinkers (16–37), OR 1.47 (95% CI 1.01–2.15); heavy drinkers (38–), OR 1.60 (95% CI 1.09–2.34).	Age, BMI, smoking habits , daily alcohol consumption .

Nilsson ⁵³	2004	Norway	Population-based nested case-cohort	43363	71%	3153	Questionnaire	Severe (95% at least weekly) heartburn or acid regurgitation during the previous 12 months	Prevalent	Daily smoking (years): <1, OR 1.0 (reference); 1–5, OR 1.2 (95% CI 0.9–1.6); 6–10, OR 1.5 (95% CI 1.2–1.8); 10–20, OR 1.7 (95% CI 1.4–1.9); >20, OR 1.7 (95% CI 1.5–1.9); p for linear trend <0.0001. Lifetime number of cigarettes smoked (thousands): <0.1, OR 1.0 (reference); 0.1–25, OR 1.1 (95 % CI 0.9–1.4); >25–50, OR 1.5 (95% CI 1.3–1.8); >50–100, OR 1.6 (95% CI 1.4–1.8); >100–200, OR 1.6 (95% CI 1.4–1.9); >200, OR 1.6 (95% CI 1.3–2.0); p for linear trend <0.0001.	Occasions of spirits, wine, or beer consumption during last two weeks: None, OR 1.0 (reference); 1–4, OR 0.9 (95 % CI 0.8–1.0); 5–10, OR 0.9 (95% CI 0.7–1.2); >10, OR 1.0 (95% CI 0.8–1.3); p for linear trend 0.54.	Age, sex, BMI, to b a c c e n e u s e , smoking, alcohol use , coffee use , asthma medication.
Nandurkar ⁶²	2004	USA	Population-based nested case-control	132	81%	16	Questionnaire	At least weekly heartburn or acid regurgitation in the past year	Prevalent	Ever smoking, OR 1.8 (95% CI 0.5–6.6).	Ever alcohol, OR 1.0 (95% CI 0.3–3.5).	Age, gender, BMI, SCL-90 somatisation score.
Mohammed ⁵⁵	2005	UK	Population-based cross sectional case-control	1533	41%	322	Questionnaire	At least weekly heartburn or acid regurgitation during the past year	Prevalent	Current smoking, OR 1.65 (95% CI 1.17–2.33).	Excess alcohol consumption (>30 units/week for men and >20 units/week for women), OR 2.96 (95% CI 1.45–6.06).	Log-BMI, irritable bowel syndrome, South Asian, family history of upper gastrointestinal disease, no educational attainment , excess alcohol, current smoking, anticholinergic drugs.

Zheng ⁵⁶	2007	Sweden	Population-based cross sectional case-control	27717	Not stated	4083	Telephone interview	At least weekly retrosternal pain or burning with antacid relief or radiation toward the neck or regurgitation of bitter fluid	Prevalent	<p>Women - monozygotic co-twin control comparison:</p> <p>Ever smoking, 1.08 (95% CI 0.66–1.74).</p> <p>Cigarettes equivalent/day: 1–9, OR 0.82 (95% CI 0.45–1.48); 10–19, OR 1.32 (95% CI 0.71–2.44); ≥20, OR 1.10 (95% CI 0.49–2.45); p for trend 0.6390.</p> <p>Men - monozygotic co-twin control comparison:</p> <p>Ever smoking, OR 1.37 (95% CI 0.70–2.66).</p> <p>Cigarettes equivalent/day: 1–9, OR 1.21 (95% CI 0.44–3.27); 10–19, OR 1.05 (95% CI 0.47–2.37); ≥20, OR 1.82 (95% CI 0.86–3.83); p for trend 0.1034.</p>	<p>Women - monozygotic co-twin control comparison:</p> <p>Alcohol, OR 0.73 (95% CI 0.45–1.19).</p> <p>Absolute alcohol grams/month): 1–150, OR 1.13 (95% CI 0.58–2.17); 151–1200, OR 0.84 (95% CI 0.45–1.59); 1201–2400, OR 0.48 (95% CI 0.22–1.04); >2400, OR 0.31 (95% CI 0.11–0.84); p for trend 0.0093.</p> <p>Men - monozygotic co-twin control comparison:</p> <p>Alcohol, OR 0.65 (95% CI 0.32–1.33).</p> <p>Absolute alcohol (grams/month): 1–150, OR 0.75 (95% CI 0.31–1.79); 151–1200, OR 0.79 (95% CI 0.34–1.83); 1201–2400, OR 0.66 (95% CI 0.26–1.64); >2400, OR 0.57 (95% CI 0.24–1.32); p for trend 0.1845.</p>	Year of birth, BMI, smoking, coffee, physical activity at work and at leisure time , education.
---------------------	------	--------	---	-------	------------	------	---------------------	--	-----------	--	--	--

Zagari ⁶³	2008	Italy	Population-based cross sectional case-control	1033	67%	245	Questionnaire	At least twice weekly heartburn or acid regurgitation during the previous 12 months	Prevalent	Never smoker, RR 1.0 (reference); former smoker, RR 0.9 (95% CI 0.6-1.2); current smoker, RR 0.8 (95% CI 0.6-1.2).	Alcohol consumption: none/occasional, RR 1.0 (reference); weekly, RR 1.1 (95% CI 0.7-1.5); daily, RR 0.8 (95% CI 0.6-1.1).	Age, sex, BMI, smoking er , alcohol consumption , coffee, medication (ASA, NSAIDs, corticosteroids), history of peptic ulcer disease, helicobacter pylori infection, hiatus hernia.
Nasseri-Moghaddam ⁵⁷	2008	Iran	Population-based cross sectional case-control	2057	82%	374	Questionnaire	At least weekly heartburn or acid regurgitation in the past 12 months	Prevalent	Positive smoking, OR 1.83 (95% CI 1.12–2.99).		Age, gender, BMI, education level , marriage, spouse and GORD history , first relative GORD history, coffee consumption , asthma, tea consumption , NSAID consumption .
Eslick ⁵⁸	2009	Australia	Population-based cross sectional case-control	672	73%	78	Questionnaire	At least weekly heartburn or acid regurgitation the past 12 months	Prevalent	Current smoker, OR 2.47 (95% CI 1.07-5.70).		Sex, age, high blood pressure, diabetes, high cholesterol.
Friedenberg ⁵⁹	2010	USA	Population-based cross sectional case-control	503	22%	129	Questionnaire	Troublesome heartburn or regurgitation ≥2 days/week or severe heartburn or regurgitation ≥1 day/week	Prevalent	Current smoking, OR 1.74 (95% CI 1.15—2.65).		Age, BMI, calcium channel blocker intake.

Pandeya ⁶⁴	2011	Australia	Population-based cross sectional case-control	1580	51%	174	Questionnaire	At least weekly heartburn or acid regurgitation in the past year	Prevalent	Never smoker, OR 1.0 (reference); current smoker, OR 0.83 (95% CI 0.52–1.33); ex-smoker, OR 1.30 (95% CI 0.93–1.83).	Alcohol consumption (drinks/week): Never drinkers, OR 1.00 (reference); <1, OR 1.47 (95% CI 0.78–2.78); 1–6.99, OR 1.03 (95% CI 0.61–1.74); 7–20.99, OR 1.37 (95% CI 0.79–2.38); 21 or more, OR 1.33 (95% CI 0.72–2.46).	Age, sex, further education, BMI, smoking status , alcohol, ASA or NSAID use in the past 5 years, physical activity, dietary factors (hot and spicy food consumption, BBQ meat and its doneness, frequency of takeaway fried, home fried food consumption).
Ford ⁶¹	2013	UK	Population-based longitudinal case-control	3418	47%	253	Questionnaire	At least weekly heartburn or acid regurgitation over the preceding 6 months	Incident	Tobacco use, OR 1.33 (99% CI 0.88–2.02).	Alcohol use, OR 0.59 (99% CI 0.34–1.04).	Age, gender, helicobacter pylori status, marital status, tobacco use , alcohol use , coffee drinker , ethnicity, social class, quality of life, irritable bowel syndrome, BMI.

Cela ⁶⁰	2013	Albania	Population-based cross sectional case-control	845	85%	101	Questionnaire	At least weekly heartburn or acid regurgitation during last year	Prevalent	Never smoker, OR 1.00 (reference); current smoker, OR 29.3 (95% CI 13.9–61.2); former smoker, OR 9.79 (95% CI 4.22–22.7).	Alcohol consumption: No/occasional, OR 1.00 (reference); moderate/heavy intake, OR 1.83 (95% CI 1.10–3.06).	Age, sex, socioeconomic variables, behavioural factors (smoking, alcohol intake, physical activity, frequency of meat and consumption, frequency of fried food consumption, BMI).
Hallan ⁵²	2015	Norway	Population-based longitudinal nested case-cohort	14916	61%	510	Questionnaire	Severe (95–98% at least weekly) heartburn or acid regurgitation during the previous 12 months	Incident	Never smokers, OR 1.00 (reference); previous smokers, OR 1.37 (95% CI 1.07–1.76); quitters, OR 1.73 (95% CI 1.31–2.27); current smokers, OR 1.29 (95% CI 1.00–1.67).	Alcohol consumption: ≤weekly, OR 1.00 (reference); >weekly, OR 0.91 (95% CI 0.70–1.19).	Age, sex, BMI change, smoking status, alcohol consumption, physical exercise, education.

*In analyses of the risk of GORD with tobacco smoking, tobacco smoking is not included as an adjustment variable. In analyses of the risk of GORD with alcohol consumption, alcohol consumption is not included as an adjustment variable.